KLP Kapitalforvaltning AS acquired a new stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 135,400 shares of the biopharmaceutical company's stock, valued at approximately $649,000. KLP Kapitalforvaltning AS owned about 0.23% of Vanda Pharmaceuticals at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. Intech Investment Management LLC acquired a new stake in Vanda Pharmaceuticals during the 3rd quarter worth about $84,000. SG Americas Securities LLC lifted its holdings in shares of Vanda Pharmaceuticals by 26.8% during the fourth quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company's stock worth $124,000 after purchasing an additional 5,459 shares during the period. Verition Fund Management LLC boosted its position in Vanda Pharmaceuticals by 7.8% in the third quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company's stock valued at $189,000 after buying an additional 2,927 shares during the last quarter. Franklin Resources Inc. boosted its position in Vanda Pharmaceuticals by 8.8% in the third quarter. Franklin Resources Inc. now owns 55,226 shares of the biopharmaceutical company's stock valued at $266,000 after buying an additional 4,449 shares during the last quarter. Finally, ClearAlpha Technologies LP increased its holdings in Vanda Pharmaceuticals by 50.0% in the 3rd quarter. ClearAlpha Technologies LP now owns 60,000 shares of the biopharmaceutical company's stock worth $281,000 after buying an additional 20,000 shares during the period. 88.14% of the stock is owned by hedge funds and other institutional investors.
Vanda Pharmaceuticals Stock Down 5.3 %
Shares of NASDAQ VNDA traded down $0.23 during midday trading on Friday, reaching $4.14. 839,490 shares of the stock were exchanged, compared to its average volume of 910,113. The firm has a market cap of $241.43 million, a price-to-earnings ratio of -12.94 and a beta of 0.72. The firm has a 50-day simple moving average of $4.66 and a two-hundred day simple moving average of $4.72. Vanda Pharmaceuticals Inc. has a twelve month low of $3.99 and a twelve month high of $6.75.
Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.06. The company had revenue of $53.19 million for the quarter, compared to analyst estimates of $51.00 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. Research analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
VNDA has been the subject of several research reports. HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Vanda Pharmaceuticals in a research note on Tuesday, April 1st. StockNews.com initiated coverage on Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They set a "hold" rating on the stock.
View Our Latest Research Report on VNDA
Insider Activity at Vanda Pharmaceuticals
In related news, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the company's stock in a transaction that occurred on Tuesday, February 25th. The shares were purchased at an average price of $4.46 per share, with a total value of $44,600.00. Following the purchase, the chief executive officer now owns 2,331,730 shares of the company's stock, valued at $10,399,515.80. The trade was a 0.43 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders acquired a total of 32,000 shares of company stock worth $151,180 in the last 90 days. Corporate insiders own 8.90% of the company's stock.
About Vanda Pharmaceuticals
(
Free Report)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Further Reading
Before you consider Vanda Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vanda Pharmaceuticals wasn't on the list.
While Vanda Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
